The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Anupam Rama - JPMorgan Chase & Co - Analyst
: Thanks, Michael. Many of you probably heard me say this at all the other sessions, but there are three ways to ask a question, right? There's the
old-school way, just raise your hand. I'll call you, it's like the new way where you go into your portal and submit a question and it comes up on this
iPad and I can ask it anonymously.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 09, 2024 / 1:15AM, SNDX.OQ - Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference
I guess there's an intermediate strategy to you can just e-mail me, and I'll still asked a question enough. So any of those work, but I will kick it off
with a question, I guess coming out of ASH, when you think about KMT2Ar and what you learned at the meeting. What are the read-throughs as
you think about what you learned at ASH KMT2Ar that's applicable to NPM1?
Question: Anupam Rama - JPMorgan Chase & Co - Analyst
: Questions from the audience? At ASH, we got a lot of combination updates and today in your presentation, you talked about starting some
combination studies this quarter as well then as a combo at the end of the year. Maybe just what is the broader sort of strategy for combinations
for revumenib?
Question: Anupam Rama - JPMorgan Chase & Co - Analyst
: Okay. Questions from the audience?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 09, 2024 / 1:15AM, SNDX.OQ - Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference
Unidentified Participant
(technical difficulty) [question is, can you expalain the branches this year you have found commercial preparedness]?
Question: Anupam Rama - JPMorgan Chase & Co - Analyst
: Additional questions from the audience. Go ahead.
Unidentified Participant
(technical difficulty) [You expected to launch in other countries in your regulatory team is prepared to move]?
Question: Anupam Rama - JPMorgan Chase & Co - Analyst
: Just to be clear that you're talking about revumenib?
Question: Anupam Rama - JPMorgan Chase & Co - Analyst
: Question, other questions from the audience? So you know, because of the size of the KMT2Ar population, there is this view out there that perhaps
this is a niche indication in acute leukemias and where would you pushback on that? Or what levers do you think the street is underappreciating
with that kind of a statement?
Question: Anupam Rama - JPMorgan Chase & Co - Analyst
: Additional questions from the audience?
Unidentified Participant
Are there other genetic gain, so mutations or changes that could be susceptible to this pathway?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 09, 2024 / 1:15AM, SNDX.OQ - Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference
Question: Anupam Rama - JPMorgan Chase & Co - Analyst
: Additional questions from the audience?
Unidentified Participant
Can you walk us through the RTOR and what that enables you to do with regulators that you might have not been able to do otherwise?
Question: Anupam Rama - JPMorgan Chase & Co - Analyst
: Any final questions? Okay. Thank you, Michael.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 09, 2024 / 1:15AM, SNDX.OQ - Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference
| 
